Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

doi:10.1097/HEP.0000000000000696

. 2024 Mar 1;79(3):E93-E94.

doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.

Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Jeffrey V Lazarus^{1

2}, Philip N Newsome³, Sven M Francque^{4

5}, Fasiha Kanwal^{6

7}, Norah A Terrault⁸, Mary E Rinella⁹

Affiliations

¹ CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA.
² Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
³ National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK.
⁴ Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
⁵ Laboratory for Experimental Medicine and Paediatrics, InflaMed Centre of Excellence, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
⁶ Sections of Gastroenterology and Hepatology and Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
⁷ VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
⁸ Gastrointestinal and Liver Disease Division, University of Southern California, Los Angeles, California, USA.
⁹ Department of Medicine, University of Chicago, Chicago, Illinois, USA.

PMID: 37983810
DOI: 10.1097/HEP.0000000000000696

Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Jeffrey V Lazarus et al. Hepatology. 2024.

. 2024 Mar 1;79(3):E93-E94.

doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.

Authors

Jeffrey V Lazarus^{1

2}, Philip N Newsome³, Sven M Francque^{4

5}, Fasiha Kanwal^{6

7}, Norah A Terrault⁸, Mary E Rinella⁹

Affiliations

¹ CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, New York, USA.
² Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
³ National Institute for Health Research Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK.
⁴ Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium.
⁵ Laboratory for Experimental Medicine and Paediatrics, InflaMed Centre of Excellence, Translational Sciences in Inflammation and Immunology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
⁶ Sections of Gastroenterology and Hepatology and Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
⁷ VA HSR&D Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
⁸ Gastrointestinal and Liver Disease Division, University of Southern California, Los Angeles, California, USA.
⁹ Department of Medicine, University of Chicago, Chicago, Illinois, USA.

PMID: 37983810
DOI: 10.1097/HEP.0000000000000696

No abstract available

PubMed Disclaimer

Comment in

Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease".
Emanuele E, Minoretti P. Emanuele E, et al. Hepatology. 2024 Jan 1;79(1):E4. doi: 10.1097/HEP.0000000000000586. Epub 2023 Aug 30. Hepatology. 2024. PMID: 37651223 No abstract available.

Cited by

Perspectives of clinical stakeholders and patients from four VA liver clinics to tailor practice facilitation for implementing evidence-based alcohol-related care.
Soyer EM, Frost MC, Fletcher OV, Ioannou GN, Tsui JI, Edelman EJ, Weiner BJ, Bachrach RL, Chen JA, Williams EC. Soyer EM, et al. Addict Sci Clin Pract. 2024 Jan 10;19(1):3. doi: 10.1186/s13722-023-00429-3. Addict Sci Clin Pract. 2024. PMID: 38200496 Free PMC article.
Time-restricted eating and supervised exercise for improving hepatic steatosis and cardiometabolic health in adults with obesity: protocol for the TEMPUS randomised controlled trial.
Camacho-Cardenosa A, Clavero-Jimeno A, Martin-Olmedo JJ, Amaro-Gahete F, Cupeiro R, Cejudo MTG, García Pérez PV, Hernández-Martínez C, Sevilla-Lorente R, De-la-O A, López-Vázquez A, Molina-Fernandez M, Carneiro-Barrera A, Garcia F, Rodríguez-Nogales A, Gálvez Peralta JJ, Cabeza R, Martín-Rodríguez JL, Muñoz-Garach A, Muñoz-Torres M, Labayen I, Ruiz JR. Camacho-Cardenosa A, et al. BMJ Open. 2024 Jan 24;14(1):e078472. doi: 10.1136/bmjopen-2023-078472. BMJ Open. 2024. PMID: 38267239 Free PMC article.
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis.
Saldarriaga OA, Wanninger TG, Arroyave E, Gosnell J, Krishnan S, Oneka M, Bao D, Millian DE, Kueht ML, Moghe A, Jiao J, Sanchez JI, Spratt H, Beretta L, Rao A, Burks JK, Stevenson HL. Saldarriaga OA, et al. JHEP Rep. 2023 Nov 3;6(1):100958. doi: 10.1016/j.jhepr.2023.100958. eCollection 2024 Jan. JHEP Rep. 2023. PMID: 38162144 Free PMC article.
Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease.
Pagkali A, Makris A, Brofidi K, Agouridis AP, Filippatos TD. Pagkali A, et al. Diabetes Metab Syndr Obes. 2024 Jan 22;17:283-294. doi: 10.2147/DMSO.S397643. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38283640 Free PMC article. Review.
Hepatic and pancreatic extracellular volume fraction analysis using contrast-enhanced CT in patients with diabetes mellitus and pre-diabetes.
Fukui H, Onishi H, Nakamoto A, Tsuboyama T, Ota T, Honda T, Kiso K, Yoshidome E, Enchi Y, Tatsumi M, Tomiyama N. Fukui H, et al. Jpn J Radiol. 2024 Jun;42(6):599-611. doi: 10.1007/s11604-024-01531-5. Epub 2024 Feb 14. Jpn J Radiol. 2024. PMID: 38351253 Free PMC article.

See all "Cited by" articles

References

1. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52.
1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86.
1. Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023. published online ahead of print, 2023 Aug 2.
1. Ratziu V, Boursier J. AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2023. published online ahead of print, 2023 Aug 3.
1. Morse DF, Sandhu S, Mulligan K, Tierney S, Polley M, Chiva Giurca B, et al. Global developments in social prescribing. BMJ Glob Health. 2022;7:e008524.

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

[1] Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52.

[2] Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–52.

[3] Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86.

[4] Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–86.

[5] Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023. published online ahead of print, 2023 Aug 2.

[6] Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2023. published online ahead of print, 2023 Aug 2.

[7] Ratziu V, Boursier J. AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2023. published online ahead of print, 2023 Aug 3.

[8] Ratziu V, Boursier J. AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2023. published online ahead of print, 2023 Aug 3.

[9] Morse DF, Sandhu S, Mulligan K, Tierney S, Polley M, Chiva Giurca B, et al. Global developments in social prescribing. BMJ Glob Health. 2022;7:e008524.

[10] Morse DF, Sandhu S, Mulligan K, Tierney S, Polley M, Chiva Giurca B, et al. Global developments in social prescribing. BMJ Glob Health. 2022;7:e008524.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Affiliations

Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature

Authors

Affiliations

Comment in

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Comment in

Similar articles

Cited by

References

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical